Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $515.03, for a total transaction of $4,892,785.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,097,878.29. This represents a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $499.73 on Friday. The firm has a 50-day simple moving average of $535.95 and a two-hundred day simple moving average of $535.72. The company has a market cap of $21.43 billion, a P/E ratio of 17.88, a price-to-earnings-growth ratio of 1.70 and a beta of 0.59. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period in the prior year, the company posted $6.41 EPS. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 26.32 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on the company. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Bank of America dropped their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of United Therapeutics in the second quarter worth about $2,868,735,000. Wellington Management Group LLP grew its stake in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares in the last quarter. Jupiter Topco LLC purchased a new stake in United Therapeutics during the 2nd quarter valued at about $450,140,000. Norges Bank acquired a new stake in United Therapeutics in the 4th quarter valued at about $293,418,000. Finally, Avoro Capital Advisors LLC raised its holdings in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.